MannKind (MNKD) News Today $6.88 +0.02 (+0.29%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period MannKind Co. (NASDAQ:MNKD) Director Steven B. Binder Sells 67,539 SharesNovember 20 at 5:46 AM | insidertrades.comLeerink healthcare analysts hold an analyst/industry conference callNovember 19 at 5:07 PM | markets.businessinsider.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from AnalystsNovember 16, 2024 | americanbankingnews.comMannKind’s Growth Momentum and Increased Confidence in Pipeline Elevate Buy RatingNovember 12, 2024 | markets.businessinsider.comMannKind Co. (NASDAQ:MNKD) Given Average Rating of "Buy" by BrokeragesShares of MannKind Co. (NASDAQ:MNKD - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the coNovember 11, 2024 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comMannKind Co. (NASDAQ:MNKD) Insider Sells $403,700.00 in StockNovember 9, 2024 | insidertrades.comMannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...November 9, 2024 | finance.yahoo.comMannKind price target raised to $7 from $5 at RBC CapitalNovember 9, 2024 | markets.businessinsider.comStuart A. Tross Sells 55,000 Shares of MannKind Co. (NASDAQ:MNKD) StockMannKind Co. (NASDAQ:MNKD - Get Free Report) insider Stuart A. Tross sold 55,000 shares of MannKind stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the transaction, the insider now directly owns 967,191 shares in the company, valued at $7,099,181.94. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.November 8, 2024 | marketbeat.comMannKind (MNKD) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comQ3 2024 MannKind Corp Earnings Call TranscriptNovember 8, 2024 | gurufocus.comMannKind Corporation (MNKD) Q3 2024 Earnings Conference Call TranscriptNovember 7, 2024 | seekingalpha.comMannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comMannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Look ForNovember 6, 2024 | finance.yahoo.comInternational Assets Investment Management LLC Grows Position in MannKind Co. (NASDAQ:MNKD)International Assets Investment Management LLC boosted its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 511.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 88,689 shares of the biopharmaceutical company's stock after bNovember 6, 2024 | marketbeat.comMannKind to Present at 2024 UBS Healthcare ConferenceNovember 5, 2024 | globenewswire.comMannKind reports results from Phase 1 study of nintedanib DPINovember 4, 2024 | markets.businessinsider.comMannKind (NASDAQ:MNKD) Reaches New 1-Year High - Here's What HappenedMannKind (NASDAQ:MNKD) Hits New 52-Week High - Still a Buy?November 4, 2024 | marketbeat.comMannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic DiseasesNovember 4, 2024 | globenewswire.comMannKind (MNKD) Scheduled to Post Earnings on ThursdayMannKind (NASDAQ:MNKD) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comMannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is OptimisticOctober 31, 2024 | msn.comMannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024October 31, 2024 | globenewswire.comFirst Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseOctober 30, 2024 | globenewswire.comMannKind (NASDAQ:MNKD) Sets New 1-Year High - Time to Buy?MannKind (NASDAQ:MNKD) Reaches New 1-Year High - Here's WhyOctober 29, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from BrokeragesMannKind Co. (NASDAQ:MNKD - Get Free Report) has received an average rating of "Buy" from the seven research firms that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the coOctober 17, 2024 | marketbeat.comSG Americas Securities LLC Takes Position in MannKind Co. (NASDAQ:MNKD)SG Americas Securities LLC bought a new stake in MannKind Co. (NASDAQ:MNKD - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 86,775 shares of the biopharmaceutical company's stock, valued at approximateOctober 16, 2024 | marketbeat.comDimensional Fund Advisors LP Invests $1.52 Million in MannKind Co. (NASDAQ:MNKD)Dimensional Fund Advisors LP purchased a new position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 291,996 shares of the biopharmaceutical company's stock, valueOctober 13, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comMannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...October 10, 2024 | finance.yahoo.comMannKind Co. (NASDAQ:MNKD) Stock Position Decreased by Squarepoint Ops LLCSquarepoint Ops LLC cut its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 45.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,878 shares of the biopharmaceutical company's sOctober 8, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by Millennium Management LLCMillennium Management LLC raised its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 189.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,744,519 shares of the biopharmaceutical company's stock after buying an additioOctober 4, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Up 3.2%MannKind (NASDAQ:MNKD) Trading Up 3.2%October 3, 2024 | marketbeat.comMannKind Leverages Tyvaso DPI Strength In Pulmonary Market ExpansionOctober 3, 2024 | seekingalpha.comMarshall Wace LLP Cuts Stake in MannKind Co. (NASDAQ:MNKD)Marshall Wace LLP cut its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 25.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 599,359 shares of the biopharmaceutical company's stock after selliOctober 3, 2024 | marketbeat.comLytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor ConferenceSeptember 30, 2024 | finance.yahoo.comMannKind Reports 30-week Results From Phase 4 INHALE-3 Study - Quick FactsSeptember 30, 2024 | markets.businessinsider.comMore Adults With Type 1 Diabetes Achieved A1C Goal (September 30, 2024 | globenewswire.comDark Forest Capital Management LP Acquires 259,257 Shares of MannKind Co. (NASDAQ:MNKD)Dark Forest Capital Management LP lifted its holdings in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 1,551.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 275,970 shares of the biopharmaceutical company's stock after pSeptember 26, 2024 | marketbeat.comAvoro Capital Advisors LLC Reduces Stock Position in MannKind Co. (NASDAQ:MNKD)Avoro Capital Advisors LLC reduced its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,759,524 shares of the biopharmaceutical compaSeptember 23, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Given Consensus Rating of "Buy" by BrokeragesShares of MannKind Co. (NASDAQ:MNKD - Get Free Report) have been given a consensus rating of "Buy" by the seven research firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. ThSeptember 22, 2024 | marketbeat.comMannKind Corporation (MNKD): Short Seller Sentiment is BearishSeptember 21, 2024 | msn.comMannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseSeptember 18, 2024 | globenewswire.comMannKind (NASDAQ:MNKD) Sets New 52-Week High at $6.50MannKind (NASDAQ:MNKD) Sets New 12-Month High at $6.50September 16, 2024 | marketbeat.comMannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Cancer StockSeptember 15, 2024 | msn.comBank of New York Mellon Corp Acquires 115,390 Shares of MannKind Co. (NASDAQ:MNKD)Bank of New York Mellon Corp lifted its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 14.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 915,248 shares of the biopharmaceutical company's stoSeptember 14, 2024 | marketbeat.comMannKind Co. to Post Q3 2024 Earnings of $0.04 Per Share, Leerink Partnrs Forecasts (NASDAQ:MNKD)MannKind Co. (NASDAQ:MNKD - Free Report) - Stock analysts at Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for MannKind in a note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forecasts that the biopharmaceutical company will post earnSeptember 11, 2024 | marketbeat.comMannKind to Present at 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comMannKind (NASDAQ:MNKD) Receives New Coverage from Analysts at Leerink PartnersLeerink Partners began coverage on shares of MannKind in a research report on Monday. They issued an "outperform" rating and a $8.00 price objective on the stock.September 9, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Insider Sells $156,500.00 in StockSeptember 7, 2024 | insidertrades.com Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. MNKD Media Mentions By Week MNKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼0.380.45▲Average Medical News Sentiment MNKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼43▲MNKD Articles Average Week Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Phibro Animal Health News AnaptysBio News Radius Recycling News Omeros News Gossamer Bio News Cara Therapeutics News Repligen News Madrigal Pharmaceuticals News Halozyme Therapeutics News Ionis Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts